Showing results (231-240 of 248) with videos related to

Sort By:
Pageof 25
Bioorganic & Medicinal Chemistry Letters|January 26, 2010
Furo[2,3-b]pyridine-based cannabinoid-1 receptor inverse agonists: synthesis and biological evaluation. Part 1John S Debenham, Christina B Madsen-Duggan, Richard B Toupence, et al.
JAMA Oncology|November 6, 2015
Erlotinib and the Risk of Oral Cancer: The Erlotinib Prevention of Oral Cancer (EPOC) Randomized Clinical TrialWilliam N William, Vassiliki Papadimitrakopoulou, J Jack Lee, et al.
Bioorganic & Medicinal Chemistry Letters|February 3, 2007
Lead optimization of 5,6-diarylpyridines as CB1 receptor inverse agonistsChristina B Madsen-Duggan, John S Debenham, Thomas F Walsh, et al.
Bioorganic & Medicinal Chemistry Letters|November 3, 2005
Synthesis of functionalized 1,8-naphthyridinones and their evaluation as novel, orally active CB1 receptor inverse agonistsJohn S Debenham, Christina B Madsen-Duggan, Thomas F Walsh, et al.
Plos Pathogens|April 16, 2016
A Subset of Latency-Reversing Agents Expose HIV-Infected Resting CD4+ T-Cells to Recognition by Cytotoxic T-LymphocytesR Brad Jones, Stefanie Mueller, Rachel O'Connor, et al.
Bioorganic & Medicinal Chemistry Letters|February 13, 2007
Substituted acyclic sulfonamides as human cannabinoid-1 receptor inverse agonistsHelen E Armstrong, Amy Galka, Linus S Lin, et al.
Pageof 25